Virios Therapeutics Inc
Change company Symbol lookup
Select an option...
VIRI Virios Therapeutics Inc
PG Procter & Gamble Co
AON Aon PLC
AFRM Affirm Holdings Inc
RMI RiverNorth Opportunistic Municipal Income Fund, Inc.
NVDA NVIDIA Corp
LBAI Lakeland Bancorp Inc
BREA Brera Holdings PLC
GVYB Golden Valley Bank
DHC Diversified Healthcare Trust
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Virios Therapeutics, Inc. is a development-stage biotechnology company focused on advancing antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (FM). The Company’s lead development candidate is IMC-1, which is a fixed dose combination of famciclovir, and celecoxib designed to synergistically suppress herpes virus replication. IMC-1 combines these two specific mechanisms of action purposely designed to inhibit herpes virus activation and replication. The Company’s pipeline product includes IMC-2 (valacyclovir and celecoxib), which is in the Phase 1 development stage. IMC-2 (valacyclovir and celecoxib) is developed for treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with Long-COVID or Post-Acute Sequelae of COVID-19 (PASC).

Price
Delayed
$1.57
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.61
Day's Low
1.54
Volume
(Light)

Today's volume of 92,039 shares is on pace to be much lighter than VIRI's 10-day average volume of 1,176,420 shares.

92,039
  • Prev Close
    1.57
  • Today's Open
    1.61
  • Day's Range
    1.54-1.61
  • Avg Vol (10-day)
    1.2M
  • Last (time)
    11:33a ET 06/07/23
  • Last (size)
    100
  • 52-Wk Range
    0.219 - 9.11
    LowHigh
  • (08/15/22 - 12/28/22)
    617.06%
  • 234.4%
  • Market Cap
    28.8M
  • Shares Outstanding
    18.3M
  • -1.24
  • --
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • --
  • 7.89
  • (% of float 05/15/23)
    2.04

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.